Kalaris Therapeutics
KLRS
88 hedge funds and large institutions have $156M invested in Kalaris Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 34 reducing their positions, and 6 closing their positions.
155% more call options, than puts
Call options by funds: $303K | Put options by funds: $119K
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
5% more funds holding
Funds holding: 84 → 88 (+4)
0.09% more ownership
Funds ownership: 1.75% → 1.84% (+0.09%)
19% less capital invested
Capital invested by funds: $192M → $156M (-$36.5M)
24% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.98M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$3.18M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.79M |
| 4 |
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
|
+$262K |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$794K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$482K |
| 3 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$349K |
| 4 |
Goldman Sachs
New York
|
-$302K |
| 5 |
HF
HRT Financial
New York
|
-$246K |
KLRS Hedge Fund Activity: Q1 2023 in Review
88 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2023, worth a combined $156M — down 19% from $192M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KLRS positions and 6 closed out — a net gain of 4 holders — while 26 added to existing stakes and 34 trimmed.
The largest buyer was Wasatch Advisors, opening a new position worth an estimated $6.98M. The largest seller was BlackRock, cutting an estimated $794K.
- 88 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2023, up from 84 in Q4 2022.
- Funds reported $156M of Kalaris Therapeutics stock for Q1 2023, down 19% quarter-over-quarter.
- 10 funds opened new Kalaris Therapeutics positions in Q1 2023 and 6 closed out, a net change of +4 holders.
- The largest Kalaris Therapeutics buyer in Q1 2023 was Wasatch Advisors, an estimated $6.98M added.
- The largest Kalaris Therapeutics seller in Q1 2023 was BlackRock, an estimated $794K sold.
Based on aggregated 13F filings for Q1 2023.